Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAC85135 with Ipilimumab for MPNs
NCT05444530Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of VAC85135 in myeloproliferative neoplasms (MPN), essential thrombocythemia (ET), myelofibrosis (MF) and 1 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Dose-limiting Toxicity and Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 79 weeks. Started Jul 2022; status: completed.
02
Drugs
VAC85135
03
Conditions
myeloproliferative neoplasms (MPN)essential thrombocythemia (ET)myelofibrosis (MF)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT05444530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05444530.